Advertisement

Clinical and Translational Oncology

, Volume 21, Issue 3, pp 380–390 | Cite as

Active study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP)

  • C. Camps HerreroEmail author
  • J. J. Reina Zoilo
  • D. Monge Martín
  • F. Caballero Martínez
  • V. Guillem Porta
  • E. Aranda Aguilar
  • A. Carrato Mena
  • E. Díaz-Rubio García
  • J. García-Foncillas López
  • M. Feijóo Saus
  • R. López López
Brief Research Article
  • 51 Downloads

Abstract

Aims

To prove if there is clinical inertia in the identification and treatment of episodes of breakthrough cancer pain (BTcP), comparing actual results from clinical practice with clinical oncologists’ prior perception.

Design

Observational and descriptive study, using information collected by practising medical oncologists, at three moments: (a) questionnaire regarding their professional judgement of the handling of patients with BTcP in their practice, (b) cross-sectional clinical screening, to detect possible existing cases of BTcP in a representative sample of their patients, (c) retrospective self-audit of clinical case histories of patients diagnosed with BTcP to find out about how it has been handled.

Participants and study period

A random sample on a state level of 108 specialists in medical oncology. 540 patients who suffer some type of cancer pain on the designated study date for each specialist (July–December 2016).

Results

The global prevalence of BTcP in the study sample covered 91.3% of the patients who were suffering some type of cancer pain. Barely 2% of the doctors surveyed suspected figures around this mark. 40.9% of the cases had not been previously detected as BTcP by their doctors. Although 90% of the patients who had previously been diagnosed with BTcP received a specific analgesic treatment for the symptoms, 42% of those patients with known BTcP were not able to control their episodes of pain.

Conclusions

Clinical inertia is a serious problem in the handling of BTcP in medical oncology services, where it is the subject of a significantly low level of detection and treatment, despite the contrasting perception of specialists.

Keywords

Breakthrough cancer pain (BTcP) Clinical inertia Prevalence of BTcP 

Notes

Acknowledgements

The Active study is a scientific initiative by the Foundation to further the Excellence and Quality of Oncology (ECO in Spanish) and the Francisco de Vitoria University in Madrid. The authors thank all of the medical oncologists who took part in the survey for their contribution to the study.

Funding

This study was funded by Kyowa Kirin Farmacéutica S.L.U., through the ECO Foundation.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This study was realized in agreement by the ethical requirements of the declaration of Helsinki, review of Scotland (October, 2000) for the investigation by human beings.

Informed consent

All persons gave their informed consent prior to their inclusion in the study.

References

  1. 1.
    Breivik H, et al. Cancer-related pain: a pan-European survey of prevalence, treatment and patient attitudes. Ann Oncol. 2009;20:1420–33.CrossRefGoogle Scholar
  2. 2.
    Gómez-Batiste J, et al. Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manage. 2002;24:45–52.CrossRefGoogle Scholar
  3. 3.
    Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81(129–34):3.Google Scholar
  4. 4.
    Caraceni A, Martini C, Zecca E, Portenoy RK, Ashby MA, Hawson G, et al. Breakthrough pain characteristics and síndromes in patients with cancer pain. An international survey. Palliat Med. 2004;18:177–83.CrossRefGoogle Scholar
  5. 5.
    Mercadante S, Zagonel V, Breda E, Arcara C, Gebbia V, Porzio G, et al. Breakthrough pain in oncology: a longitudinal study. J Pain Symptom Manage. 2010;40:183–90.CrossRefGoogle Scholar
  6. 6.
    Porta-Sales J, Garzon Rodriguez C, Julia Torras J, Casals Merchan M. Cancer-related breakthrough pain. Med Clin (Barc). 2010;135:280–5.CrossRefGoogle Scholar
  7. 7.
    Mercadante S, Radbruch L, Caraceni A, Cherny N, Kaasa S, Nauck F, et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer. 2002;94:832–9.CrossRefGoogle Scholar
  8. 8.
    O’Connor PJ, et al. Advances in patient safety, vol. 2; 2005. pp. 293–308.Google Scholar
  9. 9.
    Zeppetella G. Succesful management of breakthrough cáncer pain. London: Evolving Medicine Ltd; 2010.Google Scholar
  10. 10.
    Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13:331–8.CrossRefGoogle Scholar
  11. 11.
    Bennett D, Burton AW, Fishman S, Fortner B, McCarberg B, Miaskowski C, et al. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 1. Assessment. Pharm Ther. 2005;30:296–301.Google Scholar
  12. 12.
    Bennett D, Burton AW, Fishman S, Fortner B, McCarberg B, Miaskowski C, et al. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2. Management. Pharm Ther. 2005;30:354–61.Google Scholar
  13. 13.
    Mercadante S. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing. Crit Rev Oncol Hematol. 2011;80:460–5.CrossRefGoogle Scholar
  14. 14.
    Escobar Y, Biete i Solà A, Camba M, Gálvez R, Mañas A, Rodríguez CA Sánchez, Rodríguez D y Tuca i Rodríguez A. Diagnóstico y tratamiento del dolor irruptivo oncológico: recomendaciones de consenso. Med Paliat. 2013;20(4):150–7.Google Scholar
  15. 15.
    Branch ET, Higgins S. Inercia clínica: la dificultad de superarla. Rev Esp Cardiol. 2010;63:1399–401.CrossRefGoogle Scholar
  16. 16.
    Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, et al. Clinical inertia. Ann Intern Med. 2001;35:825–34.CrossRefGoogle Scholar
  17. 17.
    Rivera F. Primer Plan de Futuro de la Oncología Médica. Madrid. Sociedad Española de Educación Médica, 2015. Disponible en [http://www.seom.org/ultimas-noticias/105218-primer-plan-de-futuro-de-la-oncologia-medica].
  18. 18.
    Pascual López A. Dolor irruptivo: perspectivas en cuidados paliativos. Sesiones Destacadas. V Congreso de la Sociedad Española del Dolor (Salamanca, 9–12 octubre 2002).Google Scholar
  19. 19.
    Zeppetella G, et al. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage. 2000;20:87–92.CrossRefGoogle Scholar
  20. 20.
    Zeppetella G. Breakthrough pain. In: Oxford textbook of palliative medicine, 4th edn, pp. 654–661 (2010).Google Scholar
  21. 21.
    Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41:273–81.CrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2018

Authors and Affiliations

  • C. Camps Herrero
    • 1
    Email author
  • J. J. Reina Zoilo
    • 2
  • D. Monge Martín
    • 3
  • F. Caballero Martínez
    • 3
  • V. Guillem Porta
    • 4
  • E. Aranda Aguilar
    • 5
  • A. Carrato Mena
    • 6
  • E. Díaz-Rubio García
    • 7
  • J. García-Foncillas López
    • 8
  • M. Feijóo Saus
    • 9
  • R. López López
    • 10
  1. 1.Medical Oncology ServiceGeneral University Hospital of Valencia, CIBERONCValenciaSpain
  2. 2.Medical Oncology ServiceUniversity Hospital Virgen MacarenaSevilleSpain
  3. 3.Degree in Medicine, Department of Health SciencesFrancisco de Vitoria UniversityMadridSpain
  4. 4.Oncology ServiceValencian Institute of Oncology FoundationValenciaSpain
  5. 5.Oncology ServiceUniversity Hospital Reina SofíaCórdobaSpain
  6. 6.Medical Oncology ServiceUniversity Hospital Ramon y Cajal, IRYCIS, CIBERONCMadridSpain
  7. 7.Oncology ServiceClinical Hospital San CarlosMadridSpain
  8. 8.Oncology Service of the Jiménez Díaz FoundationMadridSpain
  9. 9.Medical Oncology ServiceUniversity Hospital La MoralejaMadridSpain
  10. 10.Medical Oncology ServiceUniversity Hospital Complex of Santiago de CompostelaSantiago de CompostelaSpain

Personalised recommendations